Chongqing Lummy Pharmaceutical Net Assets

Latest as of September 2025: CN¥1.85 Billion CNY ≈ $271.01 Million USD

Chongqing Lummy Pharmaceutical net assets. Based on the latest financial reports, Chongqing Lummy Pharmaceutical (300006) has net assets worth CN¥1.85 Billion CNY (≈ $271.01 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.76 Billion ≈ $404.21 Million USD) and total liabilities (CN¥910.32 Million ≈ $133.21 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 300006 year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥1.85 Billion
% of Total Assets	67.05%
Annual Growth Rate	20.63%
5-Year Change	52.92%
10-Year Change	11.45%
Growth Volatility	67.64

Net Assets of Chongqing Lummy Pharmaceutical (2006–2024)

Net assets of Chongqing Lummy Pharmaceutical from 2006 to 2024. This chart illustrates how Chongqing Lummy Pharmaceutical's net assets have evolved over time, based on quarterly financial data. See 300006 net asset quality index to measure how much of total assets are equity-financed.

Annual Net Assets for Chongqing Lummy Pharmaceutical (2006–2024)

The table below shows the annual net assets of Chongqing Lummy Pharmaceutical from 2006 to 2024. For live market cap and overall valuation, see market cap of Chongqing Lummy Pharmaceutical.

Year	Net Assets	Change
2024-12-31	CN¥1.88 Billion ≈ $275.59 Million	-11.25%
2023-12-31	CN¥2.12 Billion ≈ $310.54 Million	-2.87%
2022-12-31	CN¥2.18 Billion ≈ $319.73 Million	-1.23%
2021-12-31	CN¥2.21 Billion ≈ $323.70 Million	+79.61%
2020-12-31	CN¥1.23 Billion ≈ $180.22 Million	-25.53%
2019-12-31	CN¥1.65 Billion ≈ $241.99 Million	-4.08%
2018-12-31	CN¥1.72 Billion ≈ $252.28 Million	+0.07%
2017-12-31	CN¥1.72 Billion ≈ $252.11 Million	+2.90%
2016-12-31	CN¥1.67 Billion ≈ $245.00 Million	-0.92%
2015-12-31	CN¥1.69 Billion ≈ $247.28 Million	+66.17%
2014-12-31	CN¥1.02 Billion ≈ $148.81 Million	-9.66%
2013-12-31	CN¥1.13 Billion ≈ $164.73 Million	+58.44%
2012-12-31	CN¥710.51 Million ≈ $103.97 Million	+7.62%
2011-12-31	CN¥660.17 Million ≈ $96.60 Million	+17.55%
2010-12-31	CN¥561.59 Million ≈ $82.18 Million	+6.95%
2009-12-31	CN¥525.08 Million ≈ $76.84 Million	+281.08%
2008-12-31	CN¥137.79 Million ≈ $20.16 Million	+27.69%
2007-12-31	CN¥107.91 Million ≈ $15.79 Million	+67.59%
2006-12-31	CN¥64.39 Million ≈ $9.42 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Chongqing Lummy Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 1989.2% over the analyzed period, potentially due to dividend distributions or operating losses.

Chongqing Lummy Pharmaceutical Net Assets Breakdown (December 2024)

Chongqing Lummy Pharmaceutical net assets breakdown by equity component as of December 2024.

Component	Amount	Percentage
Common Stock	CN¥1.06 Billion	56.31%
Other Components	CN¥1.37 Billion	73.31%
Total Equity	CN¥1.88 Billion	100.00%

Chongqing Lummy Pharmaceutical Competitors by Market Cap

The table below lists competitors of Chongqing Lummy Pharmaceutical ranked by their market capitalization.

Company	Market Cap
Vestjysk Bank A/S CO:VJBA	$1.41 Billion
Mobileye Global Inc. Class A Common Stock NASDAQ:MBLY	$1.41 Billion
Daqo New Energy Corp ADR NYSE:DQ	$1.41 Billion
AnaptysBio Inc NASDAQ:ANAB	$1.41 Billion
Adecoagro S.A F:ACD	$1.41 Billion
Europris ASA OL:EPR	$1.41 Billion
Ingersoll Rand (India) Limited NSE:INGERRAND	$1.41 Billion
Ultragenyx NASDAQ:RARE	$1.41 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Chongqing Lummy Pharmaceutical's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 2,080,651,568 to 1,875,295,205, a change of -205,356,363 (-9.9%).
Net loss of 87,804,417 reduced equity.
Dividend payments of 10,764,404 reduced retained earnings.
Other comprehensive income decreased equity by 10,254,977.
Other factors decreased equity by 96,532,565.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥-87.80 Million	-4.68%
Dividends Paid	CN¥10.76 Million	-0.57%
Other Comprehensive Income	CN¥-10.25 Million	-0.55%
Other Changes	CN¥-96.53 Million	-5.15%
Total Change	CN¥-	-9.87%

Book Value vs Market Value Analysis

This analysis compares Chongqing Lummy Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 5.14x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 25.71x to 5.14x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-12-31	CN¥0.36	CN¥9.13	x
2007-12-31	CN¥0.35	CN¥9.13	x
2008-12-31	CN¥0.28	CN¥9.13	x
2009-12-31	CN¥0.99	CN¥9.13	x
2010-12-31	CN¥0.85	CN¥9.13	x
2011-12-31	CN¥0.95	CN¥9.13	x
2012-12-31	CN¥0.99	CN¥9.13	x
2013-12-31	CN¥1.61	CN¥9.13	x
2014-12-31	CN¥1.49	CN¥9.13	x
2015-12-31	CN¥2.39	CN¥9.13	x
2016-12-31	CN¥2.10	CN¥9.13	x
2017-12-31	CN¥2.07	CN¥9.13	x
2018-12-31	CN¥2.09	CN¥9.13	x
2019-12-31	CN¥1.92	CN¥9.13	x
2020-12-31	CN¥1.44	CN¥9.13	x
2021-12-31	CN¥2.17	CN¥9.13	x
2022-12-31	CN¥2.01	CN¥9.13	x
2023-12-31	CN¥1.98	CN¥9.13	x
2024-12-31	CN¥1.78	CN¥9.13	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Chongqing Lummy Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -4.68%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -11.04%
• Asset Turnover: 0.28x
• Equity Multiplier: 1.52x
Recent ROE (-4.68%) is below the historical average (3.24%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	13.30%	8.86%	0.77x	1.95x	CN¥2.12 Million
2007	22.75%	14.75%	0.77x	1.99x	CN¥13.73 Million
2008	23.87%	12.40%	0.99x	1.95x	CN¥19.11 Million
2009	7.71%	12.13%	0.51x	1.24x	CN¥-12.04 Million
2010	7.84%	11.62%	0.43x	1.58x	CN¥-12.11 Million
2011	11.71%	13.68%	0.49x	1.73x	CN¥10.65 Million
2012	8.14%	8.51%	0.44x	2.16x	CN¥-12.27 Million
2013	5.54%	8.01%	0.35x	1.99x	CN¥-49.01 Million
2014	0.93%	1.02%	0.41x	2.26x	CN¥-90.13 Million
2015	1.26%	2.14%	0.31x	1.89x	CN¥-143.43 Million
2016	0.43%	0.71%	0.40x	1.53x	CN¥-155.66 Million
2017	3.28%	4.33%	0.47x	1.62x	CN¥-113.59 Million
2018	5.77%	6.27%	0.50x	1.85x	CN¥-71.95 Million
2019	-9.97%	-8.35%	0.53x	2.25x	CN¥-310.80 Million
2020	-27.90%	-20.64%	0.50x	2.69x	CN¥-443.90 Million
2021	-4.66%	-8.20%	0.42x	1.36x	CN¥-316.16 Million
2022	-3.23%	-7.77%	0.29x	1.44x	CN¥-281.15 Million
2023	-0.43%	-1.00%	0.31x	1.39x	CN¥-216.99 Million
2024	-4.68%	-11.04%	0.28x	1.52x	CN¥-275.33 Million

Industry Comparison

This section compares Chongqing Lummy Pharmaceutical's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

Industry: Drug Manufacturers - General
Average net assets among peers: $3,531,956,811
Average return on equity (ROE) among peers: 6.92%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Chongqing Lummy Pharmaceutical (300006)	CN¥1.85 Billion	13.30%	0.49x	$1.41 Billion
Zhejiang Int'L Group Co Ltd (000411)	$3.88 Billion	11.91%	2.39x	$750.71 Million
Zhejiang Zhenyuan Share Co Ltd (000705)	$527.66 Million	3.37%	0.81x	$302.65 Million
Hunan Jingfeng Pharmaceutical (000908)	$419.38 Million	-12.58%	1.34x	$678.45 Million
Hubei Guangji Pharmaceutical Co Ltd (000952)	$449.30 Million	6.99%	0.44x	$282.40 Million
Yifan Xinfu Pharmaceutical Co Ltd (002019)	$8.71 Billion	4.62%	0.47x	$1.67 Billion
Guangdong Jiaying Pharmaceutical Co Ltd (002198)	$82.63 Million	26.76%	0.45x	$233.19 Million
Sichuan Kelun Pharmaceutical Co Ltd (002422)	$14.00 Billion	5.92%	1.29x	$9.37 Billion
Zhejiang Jolly Pharmaceutical Co Ltd (300181)	$1.41 Billion	1.82%	0.46x	$1.28 Billion
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357)	$2.30 Billion	13.46%	0.11x	$1.65 Billion

About Chongqing Lummy Pharmaceutical

SHE:300006 China Drug Manufacturers - General

Market Cap

$1.41 Billion

CN¥9.64 Billion CNY

Market Cap Rank

#7181 Global

#1457 in China

Share Price

CN¥9.13

Change (1 day)

-11.79%

52-Week Range

CN¥4.43 - CN¥10.48

All Time High

CN¥11.34